Review
Sep 2026
Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis.
BACKGROUND Advanced or metastatic soft-tissue sarcoma (STS) responds poorly to standard chemotherapy. Anlotinib has shown activity across multiple treatment lines, including first-line and maintenance therapies, though monotherapy benefit remains limited. This study aimed to quantify the efficacy of anlotinib plus PD-1...
Ahmed Farid Gadelmawla, Ahmed A. Abo Elnaga, A. Albukhari et al.
· Future Oncology · 0 citations